Method for screening pancreatic lipase inhibitory peptide, pancreatic lipase inhibitory peptide and application of pancreatic lipase inhibitory peptide
Through bioinformatics technology and molecular simulation screening, collagen peptides with pancreatic lipase inhibitory activity were obtained, which solved the side effects and high cost of existing pancreatic lipase inhibitors, and achieved a natural non-toxic and harmless PL inhibition effect. New options for obesity prevention and treatment.
Patent Information
- Application Number
- CN202411013667.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-08
AI Technical Summary
Existing pancreatic lipase inhibitors such as orlistat have side effects and high production costs. Finding natural, non-toxic, harmless and efficient alternatives to prevent and control obesity has become an important research direction.
Combining bioinformatics technology and molecular simulation docking tools, collagen peptides with pancreatic lipase inhibitory activity were screened. The specific steps include virtual hydrolysis of kohl collagen, selecting peptides with high Peptide Ranker scores, and obtaining pancreatic lipase inhibition through papain hydrolysis. Peptide.
The pancreatic lipase inhibitory peptide GFGF with PL inhibitory activity was obtained, which can bind to PL or inhibit its active site. Through hydrogen bonds and hydrophobic interactions, it has the potential to become a PL inhibitor, providing the development direction of a new PL inhibitor. High value utilization of walnut collagen.
Smart Images

Figure CN118910211A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of anti-obesity product research, and specifically relates to a method for screening a pancreatic lipase inhibitory peptide, a pancreatic lipase inhibitory peptide and an application thereof. Background Art
[0002] According to the definition of the World Health Organization (WHO), overweight or obesity refers to abnormal or excessive fat accumulation that poses a risk to health. There is increasing evidence that obesity is an important factor that increases the risk of cardiovascular disease, hypertension, hyperlipidemia, diabetes and even cancer, and is closely related to the occurrence of a variety of chronic diseases. Therefore, how to curb the continuous expansion of the obese population and treat obesity safely and effectively has become an important public health issue that needs to be solved by all mankind.
[0003] Obesity is mainly caused by the accumulation of fat due to the long-term imbalance between energy intake and consumption, and its formation process is closely related to human fat metabolism. Pancreatic lipase (PL, EC3.1.1.3), also known as triglyceride acyl hydrolase, is a water-soluble lipase produced by pancreatic cells. It can hydrolyze 50-70% of dietary fat into various free fatty acids and monoglycerides, and then combine with bile salts, cholesterol and lysophosphatidic acid in the body to form small molecular mixed lipid particles. After being absorbed by the small intestinal epithelial cells, they participate in the body's energy metabolism, while the excess small molecules that do not play a role will be resynthesized into triglycerides and accumulate in fat cells, resulting in thickening of the fat layer and obesity. PL, as a key enzyme regulating the absorption of mammalian lipid substances, has been identified as a key target for the prevention and treatment of obesity and obesity-related diseases. Therefore, the absorption of triglycerides in the daily diet can be inhibited by inhibiting PL activity, reducing the absorption of fat in the body, thereby preventing obesity. At present, the development of PL inhibitors with less or no side effects has gradually become a research hotspot in the field of obesity prevention and treatment.
[0004] Orlistat is the only lipase inhibitor currently used in clinical practice for weight loss. It is also the only anti-obesity drug that does not act on the central nervous system and does not enter the blood. However, years of clinical application have shown that orlistat has a variety of side effects that cannot be ignored. The main adverse reactions after ingestion are gastrointestinal disorders, and rare adverse reactions involve the liver, kidneys, etc., and orlistat also affects the absorption of fat-soluble vitamins and some drugs (such as hypoglycemic drugs). In addition, orlistat is a compound with multiple chiral centers, and the synthesis operation is complicated, the production cost is high, and the price is expensive. From the perspective of safety, natural compounds and their derivative inhibitors are more applicable than chemically synthesized drugs. Therefore, finding natural, non-toxic, harmless and efficient orlistat substitutes as new PL inhibitors has become an important research direction for the prevention and control of obesity.
[0005] There is increasing evidence that bioactive peptides derived from animals and plants can play an important role in PL inhibitory activity and show anti-obesity potential. Collagen peptides are collagen-based bioactive peptides with a structure that repeats the Gly-Pro-Hyp sequence. According to structure-activity relationship analysis, they have great potential to be developed into PL inhibitors. However, collagen peptides often exist in the form of mixtures after preparation. The traditional research strategy of "enzymatic preparation-separation and purification-sequence identification-activity verification" is time-consuming and labor-intensive, and low-abundance active peptides are easily missed. Bioinformatics can minimize the number of peptides prepared by determining the relationship between the structure of the peptide and its activity, and is used to quickly evaluate bioactive peptides in proteins. Based on this, the present invention intends to combine bioinformatics technology, molecular simulation docking and other tools to obtain collagen peptides with PL inhibitory activity. Summary of the invention
[0006] Based on the above technical problems, the present invention uses PL as the enzyme source and cowhide collagen as the raw material, and combines bioinformatics technology, molecular simulation docking and other tools to prepare a pancreatic lipase inhibitory peptide with PL inhibitory activity. The pancreatic lipase inhibitory peptide has the potential to become an alternative anti-obesity product.
[0007] The specific technical solution provided by the present invention is:
[0008] In a first aspect, the present invention provides a method for screening pancreatic lipase inhibitory peptides, comprising the following steps:
[0009] Different proteases were used to virtually hydrolyze cowhide collagen, and peptides with PeptideRanker scores higher than 0.5 were screened out among the peptides obtained after virtual hydrolysis, and the protease with the best enzymatic hydrolysis effect was selected;
[0010] The best protease screened was used to hydrolyze the cowhide collagen to obtain different peptide segments;
[0011] Based on the structure-activity relationship between pancreatic lipase and different peptides, the target bioactive peptides were screened and molecular docking was performed to obtain pancreatic lipase inhibitory peptides.
[0012] As a preferred embodiment of the present invention, the screened protease is papain.
[0013] As a preferred embodiment of the present invention, the mass ratio of the cowhide gelatin to papain is 50-100:1.
[0014] As a preferred embodiment of the present invention, the hydrolysis is carried out by stirring at 60° C. for 6 to 8 hours.
[0015] As a preferred embodiment of the present invention, after hydrolysis, the supernatant is centrifuged and separated and purified by a C18 column to obtain an enzymatic hydrolysate containing the pancreatic lipase inhibitory peptide.
[0016] As a preferred embodiment of the present invention, the centrifugation is carried out at a speed of 8000 r / min for 15 min.
[0017] As a preferred embodiment of the present invention, the elution solvent used for separation and purification by C18 column is an aqueous solution containing 80% ACN and 0.1% TFA by mass, and the usage ratio of the elution solvent to the lyophilized product of the enzymatic hydrolysate is 1 μL:1 μg.
[0018] In a second aspect, the present invention provides a pancreatic lipase inhibitory peptide screened according to the above method, whose amino acid sequence is GFGF.
[0019] The third aspect of the present invention provides an enzymatic hydrolysate containing the pancreatic lipase inhibitory peptide obtained according to the above method.
[0020] In a fourth aspect, the present invention provides a use of the pancreatic lipase inhibitory peptide or the enzymatic hydrolysate in the preparation of a product for inhibiting pancreatic lipase.
[0021] As a preferred embodiment of the present invention, the pancreatic lipase inhibitory peptide or the enzymatic hydrolysate is used to prepare an anti-obesity drug.
[0022] In a fifth aspect, the present invention provides an anti-obesity drug, which comprises the pancreatic lipase inhibitory peptide or the enzymatic hydrolysate, and a pharmaceutically acceptable excipient or carrier.
[0023] As a preferred embodiment of the present invention, the pancreatic lipase inhibitory peptide or the enzymatic hydrolysate is used to prepare an anti-obesity health product.
[0024] In a sixth aspect, the present invention provides an anti-obesity health product, which comprises the pancreatic lipase inhibitory peptide or the enzymatic hydrolysate, and an auxiliary material or carrier acceptable for the preparation of the health product.
[0025] The above drugs or health products can be prepared into the required dosage form by adding suitable excipients or carriers during preparation, such as granules, capsules, tablets or other liquid preparations. Exemplary optional excipients are wetting agents, thickeners, suspending agents, emulsifiers, surfactants, colorants, flavoring agents, plasticizers, suspending agents or stabilizers, etc.
[0026] Compared with the prior art, the beneficial effects of the present invention are:
[0027] The present invention combines bioinformatics technology, molecular simulation docking and other tools to obtain a pancreatic lipase inhibitory peptide GFGF with PL inhibitory activity. GFGF can bind to potential substrates or inhibitory sites (Ser153, Phe78, Phe216) of PL, and inhibits its activity mainly through hydrogen bonds and hydrophobic interactions, and has the potential to become a PL inhibitory peptide. The present invention provides a reference for the development of new PL inhibitor peptides and provides a new way for the high-value utilization of bovine collagen. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The protein hydrolysis degree after simulated enzymatic hydrolysis and the PeptideRanker score result; A, collagen alpha-1 protein sequence, B, collagen alpha-2 protein sequence;
[0029] Figure 2 is the degree of hydrolysis at different hydrolysis reaction times;
[0030] Figure 3 is the molecular weight distribution at different hydrolysis reaction times;
[0031] Figure 4 is the PL inhibitory activity of the hydrolysates (100 μg / mL) at different hydrolysis times;
[0032] Figure 5 This is the LC-MS / MS identification ion chromatogram of bovine collagen peptide;
[0033] Figure 6 is the length (A) and molecular weight distribution (B) of the identified peptides;
[0034] Figure 7 are the 2D and 3D images of the docking of GFGF and PL;
[0035] Figure 8 are the 2D and 3D images of the docking of FPLF and PL;
[0036] Fig. 9 are the 2D and 3D images of the docking of LPGF and PL;
[0037] Fig.10 are the 2D and 3D images of the docking of GLPGF and PL;
[0038] Fig.11 are the 2D and 3D images of the docking of GPPGF and PL. DETAILED DESCRIPTION
[0039] The present invention will be further described below in conjunction with specific embodiments.
[0040] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.
[0041] Example 1
[0042] Obtaining collagen peptides
[0043] 1. Experimental methods
[0044] 1.1 Computer-Assisted Analysis
[0045] The amino acid primary sequence of bovine collagen (Collagen alpha-1(I) chain: P02453; Collagen alpha-2(I) chain: P02465) was obtained from the UniProt (https: / / www.uniprot.org / ) database by searching for “Bovine collagen”.
[0046] Then, using the “ENZYME(S)ACTION” function in the BIOPEP (https: / / biochemia.uwm.edu.pl / biopep / start_biopep.php) protein database, 33 different proteases were selected to virtually hydrolyze the above proteins, and their degree of hydrolysis (DH) was obtained and analyzed.
[0047] Afterwards, the peptides obtained after simulated enzymatic hydrolysis were predicted to be bioactive peptides on the online website PeptideRanker (http: / / distilldeep.ucd.ie / PeptideRanker / ), and peptides with scores higher than 0.5 were screened, and proteases with better enzymatic hydrolysis effects were selected from them.
[0048] 1.2. Enzymatic hydrolysis of cowhide collagen
[0049] Completely dissolve 10g of cowhide gelatin in 100mL of deionized water to prepare a bovine gelatin solution, and adjust the pH value of the solution to 6.5 with 1mol / L NaOH solution. Add 0.05g of papain to the solution at an enzyme-substrate ratio of 2% (w / w), and stir and hydrolyze for 7h at 60℃, and take 10mL of samples at 1h, 2h, 3h, 4h, 5h, 6h and 7h of hydrolysis time. After each sampling, place it in a boiling water bath and heat it for 15min to inactivate the enzyme, and then cool it to room temperature. Centrifuge the mixture at 8000r / min for 15min at room temperature, and take the supernatant as the cowhide collagenase hydrolysate. Store it at 4℃ for later use.
[0050] 1.3 Determination of hydrolysis degree
[0051] The o-phthalaldehyde (OPA) method was used to determine the degree of hydrolysis of bovine collagen hydrolysate at different enzymatic hydrolysis times. The prepared OPA reagent consists of 50mM OPA (10mL), 50mM N-acetyl-L-cysteine (10mL), 20% (w / v) SDS (5mL) and 75mM borate buffer (100mM, pH 9.5). The prepared OPA reagent was stored in the dark for 1 hour before use. Accurately mix 10μL sample (or Leu standard) with 1.2mL OPA reagent and react at room temperature for 10min. The absorbance value was measured at 340nm by a UV-visible spectrophotometer (UV-8000A). The absorbance values of a series of Leu solutions with known concentrations were measured by the above method, and a standard curve of concentration (x) and absorbance (y) was drawn (y=0.0004x+0.0513, R 2 =0.9996). Substitute the absorbance value of the sample into the standard curve to obtain the concentration of free amino groups, and draw a trend curve of the degree of hydrolysis versus enzymatic hydrolysis time. The degree of hydrolysis (DH) is calculated as follows:
[0052]
[0053] Where: h is the number of partially hydrolyzed peptide bonds per gram of protein (mmol / g); h tot is the total number of peptide bonds per gram of protein (mmol / g); [NH2] is the concentration of free amino groups in the hydrolyzate (mmol / mL); V is the volume of the hydrolyzate (mL); [NH2] tot : free amino group concentration in the raw material solution (mmol / mL); V tot : Volume of raw material solution (mL).
[0054] 1.4 Molecular weight distribution analysis
[0055] The molecular weight distribution of bovine collagen hydrolysate under different enzymatic hydrolysis time was analyzed by Ultimate 3000 HPLC equipped with Phenomenex BioSP SECS2000 column. The eluent was acetonitrile aqueous solution (30%) containing 0.1% trifluoroacetic acid (v / v). The injection volume was 10 μL, the flow rate was 0.5 mL / min, and the detection wavelength was 214 nm. The chromatographic data were analyzed by Chromeleon software, and the peptide size distribution was calculated by fitting the standard sample and elution time equation. The following standards Trp (204 Da), GLV (287 Da), SGNIGFPGK (1114 Da), insulin (5700 Da) and myoglobin (17600 Da) were used to obtain the MW calibration curve (LogMW = -0.6086t + 6.9381), where MW is the molecular weight (Da) and t is the elution time (min).
[0056] 1.5. Determination of the inhibition rate of bovine collagenase hydrolysate on PL
[0057] PL inhibition test was performed on the collagen hydrolysate of cowhide using human pancreatic lipase ELISA kit according to the manufacturer's instructions. Sample wells and standard wells were set up in a 96-well plate. The contents of the sample wells were the hydrolysate samples (5 μL) with different enzymatic hydrolysis times, pancreatic lipase solution (5 μL) and 20-fold diluted sample diluent (40 μL). The contents of the standard wells were the standards (50 μL) with different concentrations (0, 10, 20, 40, 80 and 160 U / L). Three replicate wells were set up in each group, and a blank control was set up. 100 μL horseradish peroxidase (HRP) was added to the sample wells and standard wells respectively, and then incubated at 37°C for 60 minutes. After that, the liquid was discarded, and the plate was washed repeatedly with detergent for 5 times, and then 50 μL of substrate A and B were added to each well, and the plate was incubated at 37°C in the dark for 15 minutes. Finally, 50 μL of stop solution was added to each well, and the OD value at 450 nm was detected by an ELISA reader within 15 minutes. The inhibition rate of PL was calculated as follows:
[0058]
[0059] Wherein, I is the inhibition rate of bovine collagenase hydrolysate on PL; A is the enzyme activity without adding bovine collagenase hydrolysate, a is the negative control of A (no enzyme added); B is the enzyme activity with adding bovine collagenase hydrolysate, b is the negative control of B (no enzyme added).
[0060] 1.6. Identification of Collagen Peptide Sequences in Bovine Hide Based on Peptidomics Technology
[0061] (1) Sample processing
[0062] Take 200 μg of the lyophilized sample of bovine collagen hydrolysate, thoroughly re-dissolve it in 0.1% TFA / H2O, desalt the sample using a C18 desalting column after 10K ultrafiltration, and activate the C18 desalting column by adding 200 μL of methanol. Add 200 μL of 0.1% TFA / ddH2O to balance the chromatographic column; then load the sample; use 200 μL of 0.1% TFA / ddH2O for washing; add 200 μL of a mixture of trifluoroacetic acid (TFA) and acetonitrile (ACN) for elution, in which the volume concentration of trifluoroacetic acid is 0.1% and the volume concentration of acetonitrile is 80%; collect the eluate and freeze-dry it for later use.
[0063] (2) LC-MS / MS analysis
[0064] High performance liquid chromatograph: Dionex U3000. Chromatographic column: C18, 3 μm, 75μm×15cm. Mobile phase: Solvent A: 0.1% Formic acid in water; Solvent B: 0.1% Formic acid in 80% Acetonitrile / H2O.
[0065] Mass spectrometer: Thermo Scientific Q Exactive HFX. MS1 AGC: 3e6, ion injection time: 20ms; spray voltage: 4.1kV; capillary temperature: 320℃; MS2AGC: 2e4, ion injection time: 30ms; resolution setting: primary 120,000@m / z 200, ion screening window: 1.6m / z; secondary 150,000@m / z 200, fragmentation mode: HCD, energy NCE 27, parent ion scan range: m / z340-1100; Data-dependent MS / MS: Top 25; ion scan range: start from m / z 110; dynamic exclusion time: 15s.
[0066] (3) Database retrieval and de novo data analysis
[0067] The raw mass spectrometry data were analyzed using Peaks, an internationally mainstream proteomics data analysis software, and the database used was the Bos taurus database downloaded from the Uniprot website (www.uniprot.org), species number 9913.
[0068] Table 1 Data retrieval parameters
[0069]
[0070] Table 2 De novo analysis parameters
[0071]
[0072] (4) Molecular properties of peptides and prediction of binding sites
[0073] The online website PeptideRanker (http: / / distilldeep.ucd.ie / PeptideRanker / ) was used to score the screened peptides, with 0.90 as the single threshold for activity prediction. When the peptide prediction score was greater than this value, it was considered to have potential activity. The ToxinPred (https: / / webs.iiitd.edu.in / raghava / toxinpred / index.html) program was used to predict the potential toxicity of the screened peptides.
[0074] 1.7 Molecular docking
[0075] Receptor and ligand preparation: The three-dimensional structure of human pancreatic lipase (1ETH) was obtained from the PDB database (https: / / www.rcsb.org / ), and all water molecules in the crystal were removed using Pymol. The secondary structure of the PL inhibitory peptide was drawn using ChemDraw 20, and the secondary structure was converted into a tertiary structure using Chem 3D and energy minimized, and then converted to PDB format using Open Babel. The processed peptide was docked with the previously pre-processed protein complex using AutoDock tools. The center coordinates of the docking box were set to (71.979, 28.946, 144.768), the number of grid points in each direction of XYZ was set to 90×62×126, and the grid spacing was The number of dockings was set to 100, and the rest of the parameters were kept at their default values. The molecular docking results were comprehensively evaluated based on the docking energy and docking interaction energy. The interactions between receptors and ligands were analyzed using Pymol and Discovery Studio software.
[0076] 2. Data processing
[0077] Microsoft 2016 software was used for data analysis, and the experimental results were expressed as "mean ± standard deviation". SPSS22.0 statistical software was used for one-way ANOVA analysis and post hoc multiple comparisons. Duncan analysis was used to determine whether there were significant differences between the groups (P < 0.05 was considered significant). SigmaPlot 14.0 software was used for plotting.
[0078] 3. Results and analysis
[0079] 3.1 Computer-assisted analysis results
[0080] Proteins usually contain certain polypeptide fragments with specific structures and functions. Only when these polypeptide fragments are released can their biological activity be restored. Therefore, the present invention selected 33 proteases from the BIOPEP database to perform virtual full hydrolysis of bovine collagen, and then used PeptideRanker to score the biological activity of the peptides obtained after enzymatic hydrolysis. The best protease was screened out by evaluating the protein hydrolysis degree (DH) and the number of enzymatic peptides with a score greater than 0.5.
[0081] The results are as follows Figure 1 As shown in the figure, among the 33 proteases, pepsin, papain, calpain 2 and pancreatic elastase all showed higher proteolysis degrees and released more high-scoring peptides (PeptideRanker score>0.5). Especially pepsin and papain, the two types of bovine collagen released the most high-scoring peptides after being hydrolyzed by the two proteases, reaching 461 and 442 respectively.
[0082] The specific functions of peptides are determined by the properties, types and R-groups of their constituent amino acids. According to the specificity of the protease cleavage site, different types of enzymes cleave peptide bonds at different positions in the protein structure, forming PL inhibitory active peptide sequences with different amino acid compositions and lengths, resulting in differences in their activities. The inhibitory effect of peptides on PL is related to hydrophobicity. Peptides rich in hydrophobic amino acid residues or with a certain hydrophobicity have better PL inhibitory activity. Papain can cleave peptide bonds in the hydrophobic region and generate peptides with hydrophobic amino acids (Pro, Leu, Ala, Tyr and Val) at the C-terminal position, while pepsin mainly tends to cleave peptide bonds with aromatic amino acids or leucine at the amino or carboxyl ends. A study used papain to extract a highly hydrophobic and water-insoluble component from the crude protein of hydrolyzed savoyanthus vine meal, and its inhibition rate on PL was as high as 92.87±0.15% at a concentration of 125μg / mL. Another study explored the PL inhibition effect of bovine casein hydrolysates obtained from five proteases. Papain hydrolysate (substrate concentration 30g / L) had a high inhibition rate on PL, reaching 57.38±0.98%, while pepsin hydrolysate had the lowest inhibition rate, only 19.05%, which was not much different from the inhibition rate of unhydrolyzed casein on the substrate (18.38%). Therefore, the present invention finally determined to use papain to enzymatically hydrolyze bovine skin collagen.
[0083] 3.2 Changes in hydrolysis degree and molecular weight during enzymatic hydrolysis of bovine collagen
[0084] As the enzymatic hydrolysis reaction proceeds, the peptide bonds in the macromolecular proteins are continuously broken, releasing small molecular free amino acids, and the free amino acid content increases. In the present invention, the degree of hydrolysis is represented by the ratio of the free amino group concentration in the hydrolyzate to the raw material solution. By drawing a hydrolysis degree-time curve, the changing trend of cowhide collagen during the enzymatic hydrolysis process is explored.
[0085] like Figure 2 As shown in the figure, in the first hour of enzymatic hydrolysis, due to the large amount of substrate, the protein peptide bonds are quickly broken, and the free amino acid content increases significantly, which is manifested as a rapid increase in the degree of hydrolysis. As the enzymatic hydrolysis reaction proceeds, more and more proteins are broken into short peptides or amino acids by enzymatic hydrolysis. With the decrease in substrate concentration and product inhibition, the enzyme reaction rate gradually slows down, and the hydrolysis degree of the enzymatic hydrolyzate increases slowly at a uniform rate after 6 hours. Finally, after 7 hours of enzymatic hydrolysis, the hydrolysis degree of cowhide collagen reaches 26.45%. This result is similar to the research results of the preparation of bovine connective tissue collagen peptides. After the 5% (w / w) concentration of bovine connective tissue collagen solution was hydrolyzed for 7 hours under the action of papain (enzyme-substrate ratio of 50U / g), the hydrolysis degree gradually increased to 36.6%. Part of the difference may be caused by different substrate and enzyme concentrations.
[0086] Under the hydrolysis of enzymes, proteins will be broken down into peptides with smaller molecular weights, gradually forming a mixture of peptides and amino acids of different sizes. Size exclusion chromatography can be used to understand the distribution and change trend of the molecular weight of peptides in cowhide collagen enzymatic hydrolysate as the hydrolysis time increases. Figure 3 The molecular weight distribution of bovine collagen hydrolysate at different hydrolysis times. In general, the relative molecular mass distribution of the hydrolysate changes slowly over time, with the proportion of high molecular weight peptides (>10kDa and 5-10kDa) decreasing, while the proportion of low molecular weight peptides increasing (<1kDa). After 7h of hydrolysis, the molecular weight of the hydrolysate is mainly concentrated between 0.5-1kDa (39.81%) and 1-3kDa (36.90%), with peptides <0.5kDa accounting for 11.63%, and peptides >5kDa accounting for only 3.50%. This result shows that bovine collagen has been hydrolyzed into small molecular peptides by papain. The presence of a large number of small molecular weight peptides is the basis for the bovine collagen hydrolysate to exert PL inhibitory activity.
[0087] 3.3 Analysis of the inhibitory effect of cowhide collagenase hydrolysate on PL
[0088] The inhibitory effect of bovine collagen hydrolysate (100 μg / mL) at different hydrolysis times on PL activity is shown in Figure 2. Figure 4As shown. The results showed that with the increase of hydrolysis reaction time, the inhibition rate of the hydrolysate on PL continued to increase, with significant differences between 1-3h and 4-7h, and no significant difference between 3-4h. The inhibition rate of the hydrolysate at 7h reached the highest 83.09±1.04% (P<0.05). Papain hydrolyzes the peptide bonds of cowhide collagen to convert it into polypeptides, and as the hydrolysis time increases, more active peptides with inhibitory effects on PL are produced. Therefore, the inhibition rate of the hydrolysate on PL continues to increase, indicating that the polypeptide extracted from cowhide collagen has a good PL inhibition effect.
[0089] 3.4. Identification of purified bovine collagen peptides based on LC-MS / MS
[0090] Food-derived small molecule peptides have the characteristics of high activity, good stability and strong specificity. The identified PL inhibitory peptides are mainly small peptides. There is an inevitable relationship between the degree of proteolysis and the generation of active peptides. The bovine collagen hydrolysate obtained by papain hydrolysis was identified by LC-MS / MS, and its total ion current is shown in the figure Figure 5 The identified peptides were compared with the UniProt database, and a total of 1796 peptides were obtained, with lengths ranging from 5 to 23 amino acids (see Figure 6 A), of which pentapeptides accounted for the largest number of 428, followed by hexapeptides at 239 and decapeptides at 205. The number of peptides consisting of more than 12 amino acids only accounted for 6.63% of the total. Figure 6 B) is mainly concentrated between 500 and 1000 Da, with a total relative content of 72.89%. This shows that after digestion, bovine skin collagen releases a large number of short peptides, which has good potential for providing bioactive peptides.
[0091] PL is a soluble globular protein that must undergo structural changes to hydrolyze fat droplets wrapped by bile salts. Therefore, the hydrophobic bonding between PL inhibitory peptides and PL is crucial. Peptides are usually rich in hydrophobic amino acids. The online website PeptideRanker can predict whether a peptide has biological activity based on its extracellular state and amino acid composition, and score it accordingly. Peptides with a PeptideRanker score of >0.95 belonging to the collagen type in the identification results were selected, and combined with the peak area size, amino acid type and other information of the peptides, potential bioactive peptides were screened for subsequent molecular docking (see Table 3).
[0092] The results showed that 8 peptides with PeptideRanker scores > 0.95 were screened, with molecular weights concentrated between 450Da and 900Da, hydrophobicity between 8 and 12, and non-toxic.
[0093] Table 3 Activity evaluation and molecular characteristics analysis of screened peptides
[0094]
[0095]
[0096] The peptide sequences obtained by de novo sequencing had an average local credibility (ALC) value of ≥90%, and a total of 2080 peptides were identified. The length of the peptide segments ranged from 5 to 23 amino acids, and most of them were composed of 4 to 7 amino acids, accounting for 73.22% of the total, of which the number of tetrapeptides was the largest, at 386. When the molecular weight of a peptide drug exceeds 700Da, its bioavailability will decrease significantly with the increase of the molecular weight, while small peptides (2 to 6 amino acids) with a molecular weight of less than 500Da have the highest bioavailability. Therefore, the tetrapeptides were selected as the main research objects for PeptideRanker scoring, and the peptides were screened based on peak area, amino acid type and ALC value. As a result, 6 peptides with PeptideRanker scores >0.97, ALC≥95, molecular weights concentrated between 430 and 530Da, hydrophobicity between 3 and 7, and non-toxicity were selected (Table 4).
[0097] Table 4 Activity evaluation and molecular characteristics analysis of short peptides (from de novo sequencing)
[0098]
[0099] 3.5 Molecular docking
[0100] The present invention screened out 5 short peptides, FPLF, GFGF, GLPGF, GPPGF and LPGF, based on peptide sequence length, PeptideRanker score and amino acid type. They are all rich in hydrophobic amino acids, and except for GFGF, the remaining short peptides have Pro at the second or third position of the N-terminus, so their interaction patterns and action sites on pancreatic lipase (1ETH) were analyzed respectively.
[0101] Table 5 shows the molecular docking binding energy and intermolecular interaction information. The peptide LPGF has the strongest affinity with LP, with a binding energy of -3.45 kcal / mol, and GLPGF has the weakest affinity with LP, with a binding energy of -0.82 kcal / mol.
[0102] Table 5 Interaction patterns and action sites of peptides with pancreatic lipase (1ETH)
[0103]
[0104] Compared with the other four peptides, GFGF interacts with the active site on 1ETH. Figure 7As shown in Figure 2, GFGF can form two hydrogen bonds with Gln29 and Asp31 on 1ETH, with hydrogen bond distances of 2.83 and The shorter the hydrogen bond distance, the stronger the binding ability between the polypeptide and PL, which can effectively promote the formation of a stable complex between the two. At the same time, GFGF can bind to Phe78, Ser153, His264, Ile210, Leu214 and Val260 on 1ETH through van der Waals forces, among which Ser153 and His264 are the catalytic active sites of PL, and Phe78 is a hydrogen bond donor and electrostatic stabilizer, which can form an oxygen anion pore for substrate hydrolysis, which may be one of the reasons why GFGF has good pancreatic lipase inhibitory activity. In addition, GFGF also has hydrophobic interactions with Ala179, Pro181, Phe216 and Try115 on 1ETH, among which π-π interactions can increase the stability of the enzyme-polypeptide ligand complex, making it difficult to dissociate during the reaction, and π-Alkyl interactions help to enhance the stability of the complex.
[0105] Except for GFGF, the other four peptides can interact with 1ETH in various ways, but their binding to the active site cannot be observed. Among them, the peptide FPLF forms conventional hydrogen bonds with Arg338, Asp388, and Thr330 on 1ETH, and has hydrophobic interactions with Try370, Leu41, Pro236, and Met235 (see Figure 8 ); the peptide LPGF forms conventional hydrogen bonds with Glu392 and Lys96 on 1ETH, and has hydrophobic interactions with Trp339 and Lys96 (see Fig. 9 ); the peptide GLPGF forms a conventional hydrogen bond with Pro4 on 1ETH and has hydrophobic interactions with His30, Val57, and Pro4 (see Fig.10 ); the peptide GPPGF forms a conventional hydrogen bond with Ser323 on 1ETH and has a hydrophobic interaction with Val325 (see Fig.11 ).
[0106] PL consists of N-terminal and C-terminal domains, wherein the N-terminal domain is the active site, containing the catalytic three elements Ser153, Asp177 and His264, and substrate binding residues Phe78, Ile79, His152, Phe216, Trp253 and Arg257. The active site of this domain is buried under the flexible ring of the valve, making the enzyme inactive; the C-terminal domain (residues 337-449) is mainly involved in the interaction with its auxiliary factor-colipase, and this domain is a necessary condition for activating the enzyme through valve conformational changes. In order for PL to work effectively, the N-terminal domain flips so that the active site can be contacted by the substrate, forming a functional oxygen anion hole and generating an interface binding point. It is speculated that the peptide GFGF screened by the present invention can bind to pancreatic lipase through hydrophobic force because it is rich in hydrophobic amino acids, thereby preventing the N-terminal domain (catalytic site) valve from repositioning and limiting the function of lipase. It can also form a strong interaction network with the amino acid residues in the active pocket of lipase or the ion-stabilizing residue Phe78 in the oxygen ion cavity, thereby occupying the cavity of lipase to prevent the substrate from entering the active area, thereby weakening the catalytic activity of PL, delaying the digestion and absorption of triglycerides, and thus preventing the occurrence of obesity.
[0107] In the subsequent experiments, the short peptide GFGF was synthesized by chemical solid phase synthesis method (purity 98%) and entrusted to Shanghai Kepeptide Biotechnology Co., Ltd.
[0108] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. A method for screening pancreatic lipase inhibitory peptides, characterized in that: The following steps are involved: Different proteases were used to virtually hydrolyze cowhide collagen, and peptides with PeptideRanker scores higher than 0.5 were screened out among the peptides obtained after virtual hydrolysis, and the protease with the best enzymatic hydrolysis effect was selected; The best protease screened was used to hydrolyze the cowhide collagen to obtain different peptide segments; Based on the structure-activity relationship between pancreatic lipase and different peptides, the target bioactive peptides were screened and molecular docking was performed to obtain pancreatic lipase inhibitory peptides.
2. The method according to claim 1, characterized in that The protease obtained by screening is papain.
3. The method according to claim 2, characterized in that When the cowhide collagen is hydrolyzed, the mass ratio of the cowhide collagen to papain is 50-100:
1.
4. The method according to claim 3, characterized in that The hydrolysis is carried out by stirring at 60°C for 6 to 8 hours.
5. A pancreatic lipase inhibitory peptide screened according to the method according to any one of claims 1 to 4, characterized in that: Its amino acid sequence is GFGF.
6. An enzymatic hydrolysate containing the pancreatic lipase inhibitory peptide obtained according to the method according to any one of claims 1 to 4.
7. Use of the pancreatic lipase inhibitory peptide according to claim 5 or the enzymatic hydrolysate according to claim 6 in preparing a product for inhibiting pancreatic lipase.
8. The use according to claim 7, characterized in that The pancreatic lipase inhibitory peptide or the enzymatic hydrolysate is used for preparing anti-obesity products.
9. The use according to claim 8, characterized in that The product is a medicine or a health product.
Citation Information
Cited By
Cattlehide collagen active peptide as well as preparation method and application thereof
CN120818047A
